Vigil Neuroscience (VIGL) News Today $3.01 -0.04 (-1.31%) (As of 02:50 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Vigil Neuroscience (NASDAQ:VIGL) Receives "Buy" Rating from HC WainwrightNovember 12, 2024 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Joint (JYNT), Vigil Neuroscience Inc (VIGL) and Definitive Healthcare Corp (DH)November 9, 2024 | markets.businessinsider.comVigil Neuroscience Advances Key Clinical ProgramsNovember 9, 2024 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00Wedbush boosted their price objective on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a research note on Friday.November 8, 2024 | marketbeat.comVigil Neuroscience's (VIGL) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $17.00 target price on shares of Vigil Neuroscience in a report on Friday.November 8, 2024 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stakeNovember 8, 2024 | finance.yahoo.comVigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | markets.businessinsider.comVigil Neuroscience to Present at Guggenheim Healthcare Innovation ConferenceNovember 5, 2024 | markets.businessinsider.comabrdn plc Makes New $799,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL)abrdn plc purchased a new stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 235,011 shares of the company's stock, valued at approximately $799,000. abrdn plcNovember 5, 2024 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Vigil Neuroscience Inc (VIGL)October 19, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)October 9, 2024 | prnewswire.comBuy Rating Affirmed for Vigil Neuroscience Inc Amid Promising Alzheimer’s Treatment PotentialOctober 9, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Buys New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)Point72 Asset Management L.P. purchased a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,485,000 shares of the company's stock, valuedOctober 2, 2024 | marketbeat.comEnsign Peak Advisors Inc Buys 166,442 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)Ensign Peak Advisors Inc grew its stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 72.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 395,116 shares of the company's stock after acquiringSeptember 29, 2024 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in SeptemberVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 546,600 shares, a decrease of 20.3% from the August 31st total of 685,800 shares. Based on an average daily volume of 488,600 shares, the days-to-cover ratio is currently 1.1 days. Approximately 2.7% of the company's shares are sold short.September 27, 2024 | marketbeat.comFDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trialSeptember 20, 2024 | msn.comBuy Rating Affirmed for Vigil Neuroscience Inc. as FDA Lifts Clinical Hold and Phase 1 Trials Show PromiseSeptember 18, 2024 | markets.businessinsider.comVigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment TrialSeptember 17, 2024 | marketwatch.comVigil says FDA removed partial hold on Alzheimer’s candidateSeptember 17, 2024 | msn.comVigil Neuroscience, Inc.: Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927September 17, 2024 | finanznachrichten.deVigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927September 17, 2024 | globenewswire.comVigil Neuroscience to Present at Cantor Global Healthcare ConferenceSeptember 16, 2024 | globenewswire.comVigil Neuroscience (NASDAQ:VIGL) Trading Up 5%Vigil Neuroscience (NASDAQ:VIGL) Trading 5% HigherSeptember 10, 2024 | marketbeat.comVigil Neuroscience to Present at Upcoming September Investor ConferencesAugust 29, 2024 | globenewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)August 23, 2024 | prnewswire.comResearch Analysts Offer Predictions for Vigil Neuroscience, Inc.'s Q3 2024 Earnings (NASDAQ:VIGL)Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright dropped their Q3 2024 earnings per share estimates for Vigil Neuroscience in a note issued to investors on Wednesday, August 14th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($August 16, 2024 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.4% in JulyVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 884,100 shares, a drop of 20.4% from the July 15th total of 1,110,000 shares. Based on an average daily trading volume, of 563,800 shares, the short-interest ratio is currently 1.6 days. Approximately 5.2% of the company's stock are short sold.August 15, 2024 | marketbeat.comFY2027 EPS Estimates for Vigil Neuroscience, Inc. Reduced by HC Wainwright (NASDAQ:VIGL)Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright lowered their FY2027 earnings estimates for shares of Vigil Neuroscience in a research note issued on Wednesday, August 14th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.29 per share fAugust 15, 2024 | marketbeat.comBuy Rating Affirmed for Vigil Neuroscience Inc on Promising Drug Trials and Regulatory ProspectsAugust 15, 2024 | markets.businessinsider.comGuggenheim Trims Vigil Neuroscience (NASDAQ:VIGL) Target Price to $16.00Guggenheim cut their price target on shares of Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday.August 14, 2024 | marketbeat.comVigil Neuroscience, Inc.: Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | finanznachrichten.deVIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024August 13, 2024 | investorplace.comVigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | globenewswire.comVigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology GeneticsAugust 1, 2024 | finance.yahoo.comVigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)July 31, 2024 | stockhouse.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 48.4% in JulyVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a significant decline in short interest in July. As of July 15th, there was short interest totalling 1,110,000 shares, a decline of 48.4% from the June 30th total of 2,150,000 shares. Based on an average daily volume of 530,300 shares, the days-to-cover ratio is currently 2.1 days. Currently, 7.1% of the company's stock are short sold.July 26, 2024 | marketbeat.comBuy Rating Affirmed on Vigil Neuroscience’s VG-3927 Based on Positive Phase 1 Results and Strong Industry OutlookJuly 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vigil Neuroscience Inc. on Promising VG-3927 Phase 1 Study Results and Alzheimer’s Treatment Market PotentialJuly 25, 2024 | markets.businessinsider.comCoinDesk 20 Performance Update: XRP and NEAR Help Push Index UpwardJuly 25, 2024 | uk.finance.yahoo.comPromising Early Results for Vigil Neuroscience’s VG-3927 Support Strong Buy RatingJuly 25, 2024 | markets.businessinsider.comSmall Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease BimarkerJuly 25, 2024 | benzinga.comVigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's DiseaseJuly 24, 2024 | globenewswire.comVigil Neuroscience Inc: Promising Drug Development and Potential for Accelerated FDA Approval Drive Buy RatingJuly 19, 2024 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Price Target Lowered to $17.00 at HC WainwrightHC Wainwright dropped their price objective on Vigil Neuroscience from $24.00 to $17.00 and set a "buy" rating for the company in a report on Friday.July 19, 2024 | marketbeat.comVigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International ConferenceJuly 18, 2024 | globenewswire.comVigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSPJuly 18, 2024 | globenewswire.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Up 125.8% in JuneVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 2,150,000 shares, an increase of 125.8% from the June 15th total of 952,100 shares. Currently, 13.8% of the company's shares are short sold. Based on an average daily volume of 493,400 shares, the short-interest ratio is presently 4.4 days.July 11, 2024 | marketbeat.comVigil Neuroscience (NASDAQ:VIGL) Rating Reiterated by WedbushWedbush reissued an "outperform" rating and issued a $23.00 target price on shares of Vigil Neuroscience in a research report on Thursday.July 11, 2024 | marketbeat.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)July 8, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)July 8, 2024 | prnewswire.com Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. VIGL Media Mentions By Week VIGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIGL News Sentiment▼0.000.47▲Average Medical News Sentiment VIGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIGL Articles This Week▼02▲VIGL Articles Average Week Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MGTX News Today RGNX News Today AURA News Today ALLO News Today TSHA News Today SGMO News Today PRME News Today FDMT News Today ALEC News Today DNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIGL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
